1. Focal segmental glomerulosclerosis (FSGS) represents a spectrum of idiopathic and
secondary diseases affecting the glomerulus and the kidney in a similar way.
2. In adults, FSGS is the fourth most common cause of end-stage renal disease.
3. FSGS may present as either subnephrotic- or nephrotic-range proteinuria, with or without
hypertension.
4. Mutations in multiple genes that direct the structure and function of the glomerular basement
membrane have been implicated in familial and sporadic FSGS.
5. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy and treatment
of hyperlipidemia associated with FSGS are presumed to be beneficial therapies for most
patients with FSGS based on studies of proteinuric kidney diseases, although there are little
data from randomized trials specifically addressing these therapies in FSGS.
6. Primary FSGS has a high incidence of recurrence in allografts, and recurrence may lead to loss of allograft.
secondary diseases affecting the glomerulus and the kidney in a similar way.
2. In adults, FSGS is the fourth most common cause of end-stage renal disease.
3. FSGS may present as either subnephrotic- or nephrotic-range proteinuria, with or without
hypertension.
4. Mutations in multiple genes that direct the structure and function of the glomerular basement
membrane have been implicated in familial and sporadic FSGS.
5. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy and treatment
of hyperlipidemia associated with FSGS are presumed to be beneficial therapies for most
patients with FSGS based on studies of proteinuric kidney diseases, although there are little
data from randomized trials specifically addressing these therapies in FSGS.
6. Primary FSGS has a high incidence of recurrence in allografts, and recurrence may lead to loss of allograft.
No comments:
Post a Comment